前列腺特异性膜抗原 (PSMA) 诊疗整合市场报告 2025

近年来，前列腺特异性膜抗原（PSMA）诊疗试剂盒市场规模快速成长，预计将从2024年的9.2亿美元成长到2025年的10.5亿美元，复合年增长率（CAGR）为14.0%。过去几年的成长主要受放射性药物研发投入增加、前列腺癌发病率上升、放射化学试剂盒应用日益广泛以及诊断监管核准扩大等因素的推动。

前列腺特异性膜抗原 (PSMA) 诊疗一体化试剂盒市场预计将在未来几年快速成长，到 2029 年达到 17.5 亿美元，复合年增长率 (CAGR) 为 13.7%。预测期内的成长将主要受以下因素驱动：对治疗诊断学解决方案的需求不断增长、分子影像报销范围扩大、製药公司与学术机构合作日益密切以及短半衰期同位素的应用日益广泛。预测期内的关键趋势包括：试剂盒自动化技术的进步、PSMA 配体设计的创新、人工智慧在影像分析中的应用、同位素生产技术的进步以及伴随诊断技术的开发进展。

前列腺癌发病率的不断上升预计将推动前列腺特异性膜抗原 (PSMA) 诊疗一体化试剂盒市场在未来持续成长。摄护腺癌是一种发生于摄护腺的癌症，摄护腺是男性位于膀胱下方、直肠前方的小器官。前列腺癌病例的增加主要归因于人口老化。随着老龄化的增长，罹患此病的风险显着增加。 PSMA 诊疗一体化试剂盒透过提供标靶诊断方案，在前列腺癌的诊疗管理中发挥重要作用，尤其适用于早期检测和个人化治疗方案的发展。这些试剂盒将 PSMA特异性配体与放射性示踪剂结合，以提高诊断准确性，并增强疾病监测和治疗指导。例如，根据美国非营利组织美国癌症协会于 2023 年 11 月发布的估计，到 2025 年，美国预计将新增约 313,780 例前列腺癌病例，并有 35,770 人死亡。因此，前列腺癌发病率的上升正在推动 PSMA 治疗诊断试剂盒市场的成长。

为了满足日益增长的精准癌症治疗以及前列腺癌标靶诊断和治疗的需求，PSMA标靶诊疗试剂盒市场的主要企业正致力于开发创新解决方案，例如PSMA标靶放射性配体试剂盒。 PSMA靶向放射性配体试剂盒将放射性同位素与一种旨在特异性结合PSMA的配体相结合，从而实现前列腺癌的诊断成像或标靶治疗。例如，2025年3月，总部位于澳洲的放射性药物公司Telix Pharmaceuticals Limited推出了创新试剂盒“Illuccix”，用于製备镓-68戈泽肽注射。该试剂盒使医院和核子医学中心能够在註射前立即标记放射性核素，用于对PSMA阳性前列腺癌病灶进行PET成像。此试剂盒的特点包括即用型、疾病特异性标靶化、快速成像以及与治疗诊断流程的兼容性。这些优势有助于更准确地检测转移性病灶、改善治疗计划并更有效地监测治疗反应。与传统的影像诊断和非标靶治疗相比，它在诊断復发性和转移性前列腺癌以及支持个人化治疗策略的决策方面取得了显着进展。

目录

第一章执行摘要

第二章 市场特征

第三章 市场趋势与策略

第四章 市场：宏观经济情景，包括利率、通货膨胀、地缘政治、贸易战和关税，以及新冠疫情及其復苏对市场的影响

第五章 全球成长分析与策略分析框架

• 全球前列腺特异性膜抗原 (PSMA) 诊疗试剂盒：PESTEL 分析（政治、社会、技术、环境、法律因素、驱动因素和限制因素）
• 终端用户产业分析
• 全球前列腺特异性膜抗原 (PSMA) 诊疗整合试剂盒市场：成长率分析
• 全球前列腺特异性膜抗原 (PSMA) 诊疗一体化试剂盒市场表现：规模与成长，2019-2024 年
• 全球前列腺特异性膜抗原 (PSMA) 诊疗一体化试剂盒市场预测：规模与成长，2024-2029 年，2034 年预测
• 全球前列腺特异性膜抗原 (PSMA) 诊疗试剂盒：潜在市场规模 (TAM)

第六章 市场细分

• 全球前列腺特异性膜抗原 (PSMA) 诊疗一体化试剂盒市场按产品类型、性能和预测划分，2019-2024 年、2024-2029 年预测、2034 年预测
• 诊断试剂盒
• 医疗包
• 复杂治疗诊断试剂盒
• 全球前列腺特异性膜抗原 (PSMA) 诊疗一体化试剂盒市场：按应用、实际结果和预测划分，2019-2024 年、2024-2029 年预测、2034 年预测
• 摄护腺癌
• 其他癌症
• 全球前列腺特异性膜抗原 (PSMA) 诊疗一体化试剂盒市场：按最终用户划分，实际值及预测值，2019-2024 年、2024-2029 年预测值、2034 年预测值
• 医院
• 诊断中心
• 研究所
• 专科诊所
• 其他的
• 全球前列腺特异性膜抗原 (PSMA) 诊疗一体化试剂盒市场：按诊断试剂盒、类型、实际值和预测值细分，2019-2024 年、2024-2029 年预测值、2034 年预测值
• 前列腺特异性膜抗原 (PSMA) 正子断层扫描 (PET) 影像试剂盒
• 单光子发射电脑断层扫描（SPECT）成像套件
• 伴随诊断试剂盒
• 液态生物检体试剂盒
• 全球前列腺特异性膜抗原 (PSMA) 诊疗一体化试剂盒市场：按治疗试剂盒、类型、性能和预测进行细分，2019-2024 年、2024-2029 年预测、2034 年预测
• 放射性配体治疗试剂盒
• 抗体治疗试剂盒
• 基于胜肽的治疗试剂盒
• 小分子治疗试剂盒
• 全球前列腺特异性膜抗原 (PSMA) 诊疗一体化试剂盒市场：依联合诊疗一体化试剂盒类型细分，实际资料及预测资料（2019-2024 年、2024-2029 年预测值、2034 年预测值）。
• 整合成像和治疗套件
• 双功能放射性药物试剂盒
• 基于前列腺特异性膜抗原 (PSMA) 配体的诊疗一体化试剂盒
• 个人化治疗套装

第七章 区域和国家分析

• 全球前列腺特异性膜抗原 (PSMA) 诊疗一体化试剂盒市场：按地区、绩效和预测划分，2019-2024 年、2024-2029 年预测、2034 年预测
• 全球前列腺特异性膜抗原 (PSMA) 诊疗一体化试剂盒市场：按国家/地区划分，实际结果和预测，2019-2024 年、2024-2029 年预测、2034 年预测

第八章 亚太市场

第九章：中国市场

第十章 印度市场

第十一章 日本市场

第十二章：澳洲市场

第十三章 印尼市场

第十四章 韩国市场

第十五章 西欧市场

第十六章英国市场

第十七章：德国市场

第十八章：法国市场

第十九章：义大利市场

第二十章：西班牙市场

第21章 东欧市场

第22章 俄罗斯市场

第23章 北美市场

第24章美国市场

第25章：加拿大市场

第26章 南美洲市场

第27章：巴西市场

第28章 中东市场

第29章：非洲市场

第三十章：竞争格局与公司概况

• 前列腺特异性膜抗原 (PSMA) 诊疗一体化试剂盒市场：竞争格局
• 前列腺特异性膜抗原（PSMA）诊疗一体化试剂盒市场：公司概况
  • Cyclotek（Aust）Pty Ltd Overview, Products and Services, Strategy and Financial Analysis
  • Telix Pharmaceuticals Ltd Overview, Products and Services, Strategy and Financial Analysis
  • Curium Pharma Overview, Products and Services, Strategy and Financial Analysis
  • SOFIE Biosciences Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Lantheus Holdings Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章：其他领先和创新企业

• Eckert & Ziegler SE
• CellBion Co. Ltd.
• NorthStar Medical Radioisotopes
• Isotopia Molecular Imaging Ltd
• ITM Isotope Technologies Munich SE
• Full-Life Technologies Ltd
• AdvanCell Pty Ltd
• Alpha-9 Theranostics Inc.
• ABX Advanced Biochemical Compounds GmbH
• Clarity Pharmaceuticals Ltd
• Ariceum Therapeutics GmbH
• Sinotau Pharmaceutical Group
• RadioMedix Inc.
• Scintomics GmbH
• FutureChem Co. Ltd.

第32章 全球市场竞争基准化分析与仪錶板

第33章 重大併购

第34章 近期市场趋势

第35章：高潜力市场国家、细分市场与策略

• 2029年前列腺特异性膜抗原（PSMA）诊疗一体化试剂盒市场：提供新机会的国家
• 前列腺特异性膜抗原 (PSMA) 诊疗一体化试剂盒市场 2029 年展望：新兴细分市场机会
• 前列腺特异性膜抗原 (PSMA) 诊疗一体化试剂盒市场 2029 年：成长策略
  • 基于市场趋势的策略
  • 竞争对手策略

第36章附录

Prostate-specific membrane antigen (PSMA) theranostic kits are specialized tools used to detect and treat prostate cancer by targeting the PSMA protein, which is highly expressed on cancer cells. They pair a PSMA-targeted imaging agent for precise tumor localization with a therapeutic component that delivers treatment directly to the cancer cells. These kits support personalized medicine by enhancing cancer staging, monitoring treatment response, and reducing harm to healthy tissue.

The main product types of prostate-specific membrane antigen (PSMA) theranostic kits include diagnostic kits, therapeutic kits, and combined theranostic kits. Diagnostic kits detect and visualize PSMA-expressing cancer cells using imaging agents, allowing accurate tumor localization, staging, and monitoring of prostate cancer. They are used in applications such as prostate cancer and other conditions, and serve end-users including hospitals, diagnostic centers, research institutes, specialty clinics, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

The prostate-specific membrane antigen (PSMA) theranostic kits market research report is one of a series of new reports from The Business Research Company that provides prostate-specific membrane antigen (PSMA) theranostic kits market statistics, including prostate-specific membrane antigen (PSMA) theranostic kits industry global market size, regional shares, competitors with a prostate-specific membrane antigen (PSMA) theranostic kits market share, detailed prostate-specific membrane antigen (PSMA) theranostic kits market segments, market trends and opportunities, and any further data you may need to thrive in the prostate-specific membrane antigen (PSMA) theranostic kits industry. This prostate-specific membrane antigen (PSMA) theranostic kits market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The prostate-specific membrane antigen (PSMA) theranostic kits market size has grown rapidly in recent years. It will grow from $0.92 billion in 2024 to $1.05 billion in 2025 at a compound annual growth rate (CAGR) of 14.0%. The growth in the historic period was driven by growing investment in radiopharmaceutical research and development, the rising incidence of prostate cancer, increasing availability of radiochemistry kits, and expanding regulatory approvals for diagnostics.

The prostate-specific membrane antigen (PSMA) theranostic kits market size is expected to see rapid growth in the next few years. It will grow to $1.75 billion in 2029 at a compound annual growth rate (CAGR) of 13.7%. Growth in the forecast period will result from increasing demand for theranostic solutions, expanding reimbursement for molecular imaging, rising pharma-academic research collaborations, and wider availability of short-half-life isotopes. Major trends in the forecast period include technological advancements in kit automation, innovations in PSMA ligand design, AI integration for image analysis, advancements in isotope production, and progress in companion diagnostics development.

The increasing incidence of prostate cancer is expected to drive the growth of the prostate-specific membrane antigen (PSMA) theranostic kits market in the future. Prostate cancer is a type of cancer that develops in the prostate gland, a small organ in men located below the bladder and in front of the rectum. The rise in prostate cancer cases is largely due to the aging population, as the risk of developing the disease significantly increases with age. PSMA theranostic kits play a crucial role in managing prostate cancer by offering targeted diagnostic solutions, making them particularly effective for early detection and personalized treatment planning. These kits improve diagnostic accuracy by combining PSMA-specific ligands with radiotracers, enhancing disease monitoring and therapy guidance. For instance, in November 2023, the American Cancer Society, a U.S.-based nonprofit organization, estimated that approximately 313,780 new cases of prostate cancer and 35,770 deaths would occur in the United States in 2025. Therefore, the rising incidence of prostate cancer is driving the growth of the PSMA theranostic kits market.

Leading companies in the PSMA theranostic kits market are focusing on developing innovative solutions, such as PSMA-targeted radioligand kits, to meet the growing demand for precision oncology, targeted prostate cancer diagnosis, and therapy. PSMA-targeted radioligand kits combine a ligand designed to bind specifically to PSMA with a radioactive isotope for diagnostic imaging or targeted therapy of prostate cancer. For example, in March 2025, Telix Pharmaceuticals Limited, an Australia-based radiopharmaceutical company, launched Illuccix, an innovative kit for preparing Gallium-68 gozetotide injection. This kit allows hospitals and nuclear medicine facilities to label the radionuclide just before injection for PET imaging of PSMA-positive prostate cancer lesions. Unique features of the kit include its ready-to-use format, disease-specific targeting, rapid imaging capabilities, and compatibility with theranostic workflows. These advantages allow for better detection of metastatic lesions, improved treatment planning, and more effective monitoring of therapy responses. The kit's applications include diagnosing recurrent or metastatic prostate cancer and guiding personalized treatment decisions, offering a significant advancement over conventional imaging or non-targeted therapies.

In June 2023, Ariceum Therapeutics GmbH, a Germany-based biotech company, acquired Theragnostics Ltd. for an undisclosed amount. This acquisition was aimed at strengthening Ariceum Therapeutics' technological capabilities in PSMA-targeted theranostic kits and expanding its radiopharmaceutical portfolio for prostate cancer imaging. Theragnostics Ltd., a UK-based biopharmaceutical company, specializes in developing PSMA-targeted diagnostic kits, such as the 68Ga THP PSMA kit, for prostate cancer imaging.

Major companies operating in the prostate-specific membrane antigen (psma) theranostic kits market are Cyclotek (Aust) Pty Ltd, Telix Pharmaceuticals Ltd, Curium Pharma, SOFIE Biosciences Inc., Lantheus Holdings Inc., Eckert & Ziegler SE, CellBion Co. Ltd., NorthStar Medical Radioisotopes, Isotopia Molecular Imaging Ltd, ITM Isotope Technologies Munich SE, Full-Life Technologies Ltd, AdvanCell Pty Ltd, Alpha-9 Theranostics Inc., ABX Advanced Biochemical Compounds GmbH, Clarity Pharmaceuticals Ltd, Ariceum Therapeutics GmbH, Sinotau Pharmaceutical Group, RadioMedix Inc., Scintomics GmbH, FutureChem Co. Ltd.

North America was the largest region in the prostate-specific membrane antigen (PSMA) theranostic kits market in 2024. The regions covered in prostate-specific membrane antigen (PSMA) theranostic kits report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the prostate-specific membrane antigen (PSMA) theranostic kitsprostate-specific membrane antigen (PSMA) theranostic kits market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The prostate-specific membrane antigen (PSMA) theranostic kits market consists of sales of radiolabeled therapeutic agents, diagnostic kits, combination theranostic kits, antibody-based PSMA theranostics, PSMA ligand-based drug conjugates, and companion diagnostic kits. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on prostate-specific membrane antigen (psma) theranostic kits market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for prostate-specific membrane antigen (psma) theranostic kits ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The prostate-specific membrane antigen (psma) theranostic kits market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product Type: Diagnostic Kits; Therapeutic Kits; Combined Theranostic Kits
• 2) By Application: Prostate Cancer; Other Cancers
• 3) By End-User: Hospitals; Diagnostic Centers; Research Institutes; Specialty Clinics; Others
• Subsegments:
• 1) By Diagnostic Kits: Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography Imaging Kits; Single Photon Emission Computed Tomography Imaging Kits; Companion Diagnostic Kits; Liquid Biopsy Kits
• 2) By Therapeutic Kits: Radioligand Therapy Kits; Antibody-Based Therapy Kits; Peptide-Based Therapy Kits; Small Molecule Therapy Kits
• 3) By Combined Theranostic Kits: Integrated Imaging And Therapy Kits; Dual Function Radiopharmaceutical Kits; Prostate-Specific Membrane Antigen (PSMA) Ligand-Based Theranostic Kits; Personalized Treatment Kits
• Companies Mentioned: Cyclotek (Aust) Pty Ltd; Telix Pharmaceuticals Ltd; Curium Pharma; SOFIE Biosciences Inc.; Lantheus Holdings Inc.; Eckert & Ziegler SE; CellBion Co. Ltd.; NorthStar Medical Radioisotopes; Isotopia Molecular Imaging Ltd; ITM Isotope Technologies Munich SE; Full-Life Technologies Ltd; AdvanCell Pty Ltd; Alpha-9 Theranostics Inc.; ABX Advanced Biochemical Compounds GmbH; Clarity Pharmaceuticals Ltd; Ariceum Therapeutics GmbH; Sinotau Pharmaceutical Group; RadioMedix Inc.; Scintomics GmbH; FutureChem Co. Ltd.
• Countries:

Table of Contents

1. Executive Summary

2. Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Characteristics

3. Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Trends And Strategies

4. Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Growth Analysis And Strategic Analysis Framework

• 5.1. Global Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Growth Rate Analysis
• 5.4. Global Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Total Addressable Market (TAM)

6. Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Segmentation

• 6.1. Global Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Diagnostic Kits
• Therapeutic Kits
• Combined Theranostic Kits
• 6.2. Global Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Prostate Cancer
• Other Cancers
• 6.3. Global Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Diagnostic Centers
• Research Institutes
• Specialty Clinics
• Others
• 6.4. Global Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Sub-Segmentation Of Diagnostic Kits, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography Imaging Kits
• Single Photon Emission Computed Tomography Imaging Kits
• Companion Diagnostic Kits
• Liquid Biopsy Kits
• 6.5. Global Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Sub-Segmentation Of Therapeutic Kits, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Radioligand Therapy Kits
• Antibody Based Therapy Kits
• Peptide Based Therapy Kits
• Small Molecule Therapy Kits
• 6.6. Global Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Sub-Segmentation Of Combined Theranostic Kits, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Integrated Imaging And Therapy Kits
• Dual Function Radiopharmaceutical Kits
• Prostate-Specific Membrane Antigen (PSMA) Ligand Based Theranostic Kits
• Personalized Treatment Kits

7. Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Regional And Country Analysis

• 7.1. Global Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market

• 8.1. Asia-Pacific Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market

• 9.1. China Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Overview
• 9.2. China Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market

• 10.1. India Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market

• 11.1. Japan Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Overview
• 11.2. Japan Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market

• 12.1. Australia Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market

• 13.1. Indonesia Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market

• 14.1. South Korea Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Overview
• 14.2. South Korea Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market

• 15.1. Western Europe Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Overview
• 15.2. Western Europe Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market

• 16.1. UK Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market

• 17.1. Germany Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market

• 18.1. France Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market

• 19.1. Italy Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market

• 20.1. Spain Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market

• 21.1. Eastern Europe Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Overview
• 21.2. Eastern Europe Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market

• 22.1. Russia Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market

• 23.1. North America Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Overview
• 23.2. North America Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market

• 24.1. USA Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Overview
• 24.2. USA Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market

• 25.1. Canada Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Overview
• 25.2. Canada Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market

• 26.1. South America Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Overview
• 26.2. South America Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market

• 27.1. Brazil Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market

• 28.1. Middle East Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Overview
• 28.2. Middle East Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market

• 29.1. Africa Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Overview
• 29.2. Africa Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Competitive Landscape And Company Profiles

• 30.1. Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Competitive Landscape
• 30.2. Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Company Profiles
  • 30.2.1. Cyclotek (Aust) Pty Ltd Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Telix Pharmaceuticals Ltd Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Curium Pharma Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. SOFIE Biosciences Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Lantheus Holdings Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Other Major And Innovative Companies

• 31.1. Eckert & Ziegler SE
• 31.2. CellBion Co. Ltd.
• 31.3. NorthStar Medical Radioisotopes
• 31.4. Isotopia Molecular Imaging Ltd
• 31.5. ITM Isotope Technologies Munich SE
• 31.6. Full-Life Technologies Ltd
• 31.7. AdvanCell Pty Ltd
• 31.8. Alpha-9 Theranostics Inc.
• 31.9. ABX Advanced Biochemical Compounds GmbH
• 31.10. Clarity Pharmaceuticals Ltd
• 31.11. Ariceum Therapeutics GmbH
• 31.12. Sinotau Pharmaceutical Group
• 31.13. RadioMedix Inc.
• 31.14. Scintomics GmbH
• 31.15. FutureChem Co. Ltd.

32. Global Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market

34. Recent Developments In The Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market

35. Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market High Potential Countries, Segments and Strategies

• 35.1 Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer